SSGJ-706 + pemetrexed + carboplatin

SSGJ-706 + pemetrexed + carboplatin is a combination therapy being investigated for the treatment of advanced non-small cell lung cancer (NSCLC) and other advanced solid tumors. **SSGJ-706** is a recombinant bispecific antibody developed by Sansheng Guojian (Sunshine Guojian Pharmaceutical) that can bind two targets associated with tumor immunosuppressive function, promoting T cell activation and tumor killing. **Pemetrexed** is an antifolate chemotherapeutic agent that inhibits folate-dependent enzymes involved in DNA and RNA synthesis. **Carboplatin** is a platinum-containing chemotherapeutic agent that induces DNA crosslinks, leading to apoptosis. The combination is under clinical evaluation for enhanced anti-tumor efficacy via both direct cytotoxic and immune-mediated mechanisms, particularly in advanced NSCLC[1][2][3][5].